2-Amino-5-Bromothiazole Monohydrobromide

Within current industrial synthetic frameworks targeting ATP-competitive tyrosine kinase pharmacophores, 2-amino-5-bromothiazole monohydrobromide serves as the electrophilic coupling partner in palladium-catalyzed sp²–sp² cross-coupling cascades that construct the 5-aryl-2-aminothiazole hinge-binding motif found in multiple FDA-approved oncology agents. The monohydrobromide salt is freebased directly in the reaction vessel using 1.05–1.15 equivalents of aqueous potassium carbonate prior to addition of 0.5–1.0 mol% tetrakis(triphenylphosphine)palladium(0) and 1.2 equivalents of the requisite arylboronic acid pinacol ester. Reactions proceed in a degassed 3:1 (v/v) tetrahydrofuran/water mixture at a controlled jacket temperature of 62–68 °C for 6–8 hours under nitrogen break-line pressure, with in-process HPLC monitoring at 254 nm confirming consumption of the bromothiazole component to ≤0.5 area%. On 2000 L glass-lined reactors equipped with retreat-curve impellers and side-baffle temperature probes, exotherm management dictates that the boronic acid be charged in three equal portions at 55 °C; failure to stage this addition has been documented to generate a 12–15 °C thermal spike that elevates palladium black formation and raises residual metal content in the crude isolate beyond the actionable limit. Post-reaction workup involves Celite®-assisted hot filtration through a 5 μm jacketed sparkler filter maintained at 50 °C, a 5% w/w brine wash to strip water-soluble phosphine oxide byproducts, and vacuum distillation of the organic phase to 10% original volume before drowning into 4 volumes of chilled isopropanol. The crystallized 5-aryl-2-aminothiazole intermediate is isolated via centrifuge filtration and dried in a conical tumble dryer at 40–45 °C under −0.08 MPa for 12 hours, achieving a loss on drying of ≤0.3%. The terminal API produced through this validated route is dasatinib monohydrate, with the bromothiazole intermediate additionally deployed in the manufacture of investigational VEGFR-2 and c-Met inhibitors currently in phase II clinical evaluation. Regulatory compliance across this value chain is governed by ICH Q7 for GMP intermediate production, ICH Q3D elemental impurity risk profiling with palladium limits verified by ICP-MS per USP <232>/<233> (acceptance criterion: <10 μg/g for oral solid dosage parenteral introduction), and ICH Q3C residual solvent limits whereby batch release requires THF below 720 ppm and isopropanol below 5000 ppm as determined by headspace GC-FID.

In Cefdinir and Cefditoren Pivoxil Manufacturing Routes — Where Does the Bromine Atom Direct Regioselective Acylation at the 2-Amino Group?

Second-generation oral cephalosporin antibiotics require a (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl side chain whose construction can be executed with 2-amino-5-bromothiazole monohydrobromide as the heterocyclic template, exploiting the bromine substituent at the 5-position to block electrophilic aromatic substitution and ensure that subsequent N-acylation occurs exclusively at the 2-amine nitrogen. The salt is suspended in anhydrous dichloromethane at −5 to 0 °C and treated with 1.0 equivalent of N-methylmorpholine to liberate the free amine in situ, followed by slow addition of 0.95–0.98 equivalents of the mixed anhydride generated from (Z)-2-methoxyimino-2-(2-aminothiazol-4-yl)acetic acid and pivaloyl chloride. The slight undercharge relative to the bromothiazole substrate prevents diacylated bis-side chain impurities that are difficult to purge in subsequent stages. Field-failure investigations on 3000 L glass-lined production vessels have traced reactor fouling and off-specification color values to moisture ingress above 150 ppm water in the dichloromethane stream; thus, the solvent is pre-dried through a molecular sieve column achieving <50 ppm H₂O before batch loading, and the acylation is run under a positive nitrogen flow of 0.05 MPa. The reaction is quenched after 3 hours by transfer into 5 volumes of deionized water at 5 °C, and the organic layer is washed sequentially with 0.5 N HCl and saturated sodium bicarbonate to remove unreacted amine and acid species. Crystallization from ethyl acetate/n-heptane (2:5 v/v) with seeding at 38 °C yields the protected side-chain acid as an off-white crystalline powder with a differential scanning calorimetry onset of 178–182 °C, which is subsequently activated as the mercaptobenzothiazole ester for 7-aminocephalosporanic acid coupling. The terminal dosage forms manufactured from this cephem scaffold are cefdinir capsules and cefditoren pivoxil tablets, both classified as BCS Class IV compounds requiring micronization to D90 <10 μm for adequate bioavailability. Applicable standards for the bromothiazole-derived side-chain active ester include compliance with the Japanese Pharmacopoeia related substances monograph (total impurities <1.0% by HPLC area) and the European Pharmacopoeia test for N, N-dimethylaniline (<20 ppm), a prohibited amine which can arise from dimethylformamide degradation in upstream amidation chemistry when such solvents are present.

SDHI Fungicide Library Expansion via 2-Amino-5-bromothiazole Monohydrobromide

Incorporation of the 5-bromo-2-aminothiazole fragment into succinate dehydrogenase inhibitor (SDHI) discovery programs enables parallel synthesis of carboxamide libraries by amide bond linking of the amine to pyrazole-4-carboxylic acid derivatives and subsequent Suzuki diversification at the bromine site to probe the hydrophobic pocket of the ubiquinone-binding domain. In process chemistry terms, the monohydrobromide is preferred over the free base for kilogram-scale amidations because the salt form eliminates oxidative discoloration observed during storage of the neat amine, which otherwise causes batch rejection due to APHA color values exceeding 200 in the final technical concentrate. The coupling is executed in anhydrous dimethylformamide at 0–5 °C using 1.0 equivalent of the bromothiazole salt, 1.05 equivalents of the pyrazole acid chloride (generated from the acid and thionyl chloride in toluene), and 1.2 equivalents of triethylamine as acid scavenger, with the triethylamine hydrochloride precipitate removed by pressure nutsche filtration through a 10 μm polypropylene cloth. The amide intermediate is not isolated; the dimethylformamide solution is diluted with 2 volumes of toluene, washed neutral, and directly submitted to the bromine-displacement step with 1.1 equivalents of 3-chlorophenylboronic acid under 0.3 mol% Pd(OAc)₂/SPhos catalysis at 80–85 °C for 4 hours. Agrochemical regulatory frameworks applicable to the bromothiazole-derived SDHI candidates require compliance with FAO Manual on Development and Use of Specifications for Pesticides (2016 revision) and OECD Test No. 307 for aerobic soil transformation studies, since the brominated heterocycle and its des-bromo metabolite must demonstrate half-lives below 30 days in loam soil to meet Annex II registration criteria in the EU under Regulation (EC) 1107/2009. The end-use products from this chemical sequence are formulated as 250 g/L suspension concentrates or 20% w/w water-dispersible granules, distributed under identifiers such as fluxapyroxad analogs and pydiflumetofen structural probes for cereal leaf spot control.

A parallel application trajectory with considerably narrower processing latitude exists in the synthesis of thiazole-based heterocyclic disperse dyes for high-temperature polyester exhaustion dyeing, where 2-amino-5-bromothiazole monohydrobromide is diazotized in concentrated sulfuric acid and coupled to N-alkylated aniline derivatives to introduce a red-shift of approximately 40–50 nm relative to the des-bromo analog, moving the λ_max from yellow-orange into the ruby-red segment without the use of regulated azo-benzidine substrates. The salt is charged portionwise into 98% sulfuric acid at 0–5 °C, and nitrosylsulfuric acid in stoichiometric excess of 5% relative to the amine is added dropwise while maintaining internal temperature below 8 °C—a threshold crossing that accelerates nitrosyl decomposition and yields a viscous tar that blocks the glass-lined reactor bottom valve. The diazonium liquor is clarified through a sintered Hastelloy C-276 filter and combined with the coupling component pre-dissolved in a 10% sulfamic acid solution at 0 °C; coupling pH is self-buffered by the proton sponge effect of the tertiary amine-substituted coupler and is maintained between 0.5–1.5 throughout the six-hour addition. Following drowning into 30 volumes of iced water, the precipitate is isolated on a plate-and-frame filter press, washed to neutral conductivity, and drum-dried at 80 °C under reduced pressure. Zhejiang Provincial Textile Testing Center dye uptake measurements on 100% PET knitted fabric under 130 °C high-temperature pressure dyeing conditions (SDIBL Sample 3 dyeing machine at liquor ratio 1:20) gave a build-up yield of 92% exhaustion relative to C.I. Disperse Red 167:1 at equivalent depth. Finished goods are standardized to 40% dye content by blending with sodium lignosulfonate dispersant and milled to a Fisher sub-sieve particle size of 0.5–1.5 μm for compatibility with automated liquid dispensing systems. Relevant compliance is aligned with the ZDHC Manufacturing Restricted Substances List v3.0, with targeted monitoring for chlorinated benzenes (<50 ppm each) and PCB (<10 ppm total), and the OEKO-TEX® Standard 100 Annex 4 for textile auxiliaries, calling for total extractable heavy metals below 10 ppm by ICP-OES.

When Free-Base Sensitivity Limits Throughput in Amide Bond Installations for Protease Inhibitor Peptidomimetics

Process scale-up of certain HIV-1 protease inhibitor candidates incorporating a 2-aminothiazole-terminated P2-ligand has established that the monohydrobromide salt form resolves an otherwise dominating instability of the free amine toward atmospheric carbon dioxide and moisture, which forms a non-reactive carbamate crust on bulk storage containers and leads to vessel-to-vessel molar ratio drift exceeding ±3% when tared under ambient air. The salt is directly treated with 1.05 equivalents of N,N-diisopropylethylamine in dimethylacetamide at −10 °C, generating the active free amine in situ exactly at the moment of chloroformate activation of the peptide backbone carboxylic acid, thus ensuring a 1:1 stoichiometric coupling within an acceptable tolerance of ±0.5 mol% as verified by online ReactIR monitoring of the carbonyl stretching band at 1640 cm⁻¹. The peptidomimetic assembly is carried out on a 500 L Hastelloy reactor under an argon sweep to exclude oxygen, which otherwise promotes a radical dimerization of the aminothiazole ring detected as a +482 Da impurity in the LC-MS chromatogram of the crude reaction mass. After quenching with 0.5 M HCl and extraction into ethyl acetate, the protected tetrapeptide intermediate is crystallized from methyl tert-butyl ether/heptane, isolated by a 0.5 m² agitated nutsche filter-dryer, and dried to 0.1% water by Karl Fischer titration before immediate transfer into the subsequent Boc deprotection step with trifluoroacetic acid/triisopropylsilane at 20 °C. The terminal compounds are formulated as 200 mg film-coated tablets or ritonavir-boosted combinations, and the associated quality dossiers reference compliance with ICH Q6A decision trees for specification setting of starting materials, specifically the justification of the bromothiazole intermediate purity at >99.0% by HPLC 220 nm with acceptance of <0.15% of the des-bromo analog as a process-related impurity, and ICH M7 (R2) for mutagenic impurity risk assessment, where the bromothiazole structure is classed as a Class 3 alert due to the aryl bromide moiety, requiring purge factor calculations per Teasdale et al. methodology to demonstrate that residual levels in the final drug substance do not exceed 1.5 μg/day threshold of toxicological concern.